Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

IMPORTANCE: Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal premature aging disease. There is no approved treatment. OBJECTIVE: To evaluate the association of monotherapy using the protein farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS. DESI...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA
Главные авторы: Gordon, Leslie B., Shappell, Heather, Massaro, Joe, D’Agostino, Ralph B., Brazier, Joan, Campbell, Susan E., Kleinman, Monica E., Kieran, Mark W.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2018
Предметы:
Preliminary Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933395/
https://ncbi.nlm.nih.gov/pubmed/29710166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.3264
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы